AI-generated analysis. Always verify with the original filing.
PMV Pharmaceuticals, Inc. reported full year 2025 financial results including a net loss of $77.7 million and cash of $112.9 million as of December 31, 2025, providing runway to end of Q2 2027. The company highlighted progress in the PYNNACLE Phase 2 trial for rezatapopt and plans NDA submission in Q1 2027 for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutation.
Event Type
Disclosure
Mandatory
Variant
8-K
of this Form 8-K, including the attached Exhibit 99.1, is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities
Financial Statements and Exhibits. (d) Exhibits : Exhibit Number Description 99.1 Press Release issued by PMV Pharmaceuticals, Inc., dated March 6, 2026. 104 Co
| Metric | Value | Basis |
|---|---|---|
| Net loss | $-77.7K | GAAP |
| Research and development expenses | $69.9K | GAAP |
| General and administrative expenses | $16.3K | GAAP |
| Net loss per share | $-1.48 | GAAP |
Cash runway
—